GC Cell

Autologous CIK immune cell therapy used as adjuvant treatment after hepatocellular carcinoma resection, with a Phase 3 trial in pancreatic cancer under way; in July 2026 it was listed under antineoplastic cell and gene therapy (L01XL) in the WHO ATC classification.

Allogeneic CD5-targeting CAR-NK cell therapy candidate that also expresses IL-15; a Phase 1 trial in relapsed or refractory NK/T-cell lymphoma is ongoing and moved into Phase 1b in October 2026.

Offers cell banking, clinical and commercial manufacturing, process development and quality testing from a 20,806 m2 facility in Yongin, Gyeonggi-do (four floors above ground, two below) with 14 clean rooms (18,000 packs a year on an Immuncell-LC basis), together with Made Scientific's sites in Princeton and Newark, New Jersey.

Runs specimen testing for a network of about 5,000 healthcare institutions, bio-logistics and cord blood banking.

Immuncell-LC was reclassified in the WHO ATC system from other immunostimulants (L03AX) to antineoplastic cell and gene therapy (L01XL), effective January 2027.

Korea's Ministry of Food and Drug Safety approved therapeutic-use access to GCC2005 at Seoul National University Hospital for peripheral T-cell lymphoma patients with limited treatment options.

Moved the GCC2005 trial into Phase 1b and dosed the first participant; the aims are dose optimisation and confirming the recommended Phase 2 dose, with up to six Korean trial sites.